Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 4

Initial efficacy (6–12 months) of treatment with infliximab or adalimumab in rheumatoid arthritis patients reaching remission.

	Anti-TNFi Ab-negative; = 66	Anti-TNFi Ab-positive; = 9
DAS28(CRP)	2.20 (1.5–3.3)	1.4 (0.9–1.2)	0.212
EULAR good responders, (%)	52 (79)	6 (67)	0.503

Continuous variables are expressed as medians (interquartile ranges); DAS28(CRP): decrease in disease activity score in 28 joints; EULAR: European League Against Rheumatism.